Belite Bio’s Promising Clinical Trials and Strong Financial Position Justify Buy Rating
Leerink Partners analyst Marc Goodman has reiterated their bullish stance on BLTE stock, giving a Buy rating yesterday. Marc Goodman has given ...
Strong Performance and Growth Potential for Axsome Therapeutics Drives Increased Price Target
Analyst Marc Goodman of Leerink Partners maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), boosting the price ...
The New York Times1d
New York Times - Top Stories
At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...